<DOC>
	<DOC>NCT00635713</DOC>
	<brief_summary>The main purpose of this study is to compare the effect of 2 doses of FASLODEX with 1 dose of ARIMIDEX in terms of time to tumor progression in postmenopausal women with advanced breast cancer.</brief_summary>
	<brief_title>Second Line Breast Cancer Trial</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>postmenopausal women with confirmation of breast cancer objective evidence of recurrence or progression of breast cancer no more than 1 prior hormonal therapy for breast cancer presence of lifethreatening metastatic visceral disease previous treatment with FASLODEX, ARIMIDEX or any aromatase inhibitor for breast cancer more than 1 prior endocrine medical treatment for advanced breast cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Advanced breast cancer, FASLODEX, ARIMIDEX, Fulvestrant, Anastrozole, postmenopausal</keyword>
</DOC>